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Abstract
Introduction We present our results from the first 6 years with
mechanical thrombectomy in the treatment of ischemic
stroke.
Methods Every patient treated with mechanical thrombectomy
for acute ischemic stroke from September 2005 to December
2011 was consecutively included in this retrospective analysis.
Baseline and outcome data were retrieved from computerized
records at the hospital. National Institute of Health Stroke Scale
(NIHSS) score and the modified Rankin Scale (mRS) score
were used as outcome parameters. Favorable outcome was
defined as a mRS score of 0–2, corresponding to independence
in activities of daily living. We also evaluated revascularization
and severe adverse events, with focus on symptomatic intra-
cranial hemorrhage.
Results Good functional outcome (mRS 0–2) was achieved in
50 % (120/240) of all patients. For patients with no neurolog-
ical deficit prior to stroke onset (i.e., mRS=0 before stroke),
the proportion with good functional outcome was 54 %.
Symptomatic hemorrhages occurred in 4.6 % of the cases
(5.7 % in the anterior circulation).
Conclusion In summary, our results supports that mechan-
ical thrombectomy is a safe and effective method to restore
blood flow in selected patients suffering from an acute
ischemic stroke.
Keywords Mechanical thrombectomy . Ischemic stroke .
mRS . NIHSS . Symptomatic hemorrhage
Introduction
Recanalization after large vessel occlusion is proven to be an
important predictor for favorable outcome in acute ischemic
stroke [1, 2]. Intravenous thrombolysis (IVT) with alteplase
(recombinant tissue plasminogen activator, rt-PA) has been
thoroughly investigated in several randomized controlled
studies and is shown to be a reasonably safe and effective
treatment [3–8]. However, depending on the time of onset,
5–15 patients have to be treated in order to significantly
improve the outcome of one individual [6]. The search for
alternative or complementary methods has consequently con-
tinued. Mechanical thrombectomy represents such treatment
method that has been developed during the last decade [9, 10].
Positive data from mechanical thrombectomy has been pub-
lished severally in both single and multicenter studies and
registries [11–16]. Many of these, however, include a limited
number of patients. In this retrospective study, the safety and
effectiveness of thrombectomy in the first 6 years of practice
in our institution are studied in 240 consecutive patients,
representing one of largest cohorts investigated.
Material and methods
Clinical setup
Mechanical thrombectomy was initiated at the Karolinska
University Hospital in September 2005 until December 2011
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in which 240 thrombectomies had been performed. During this
6-year period, endovascular therapy was provided on a 24/7
basis by initially two and eventually four neurointerventionalists
at the Department of Neuroradiology, the sole provider of
neurointerventional care in the Stockholm area, with a catch-
ment population of more than twomillion. Every patient treated
with mechanical thrombectomy for acute ischemic stroke from
September 2005 to December 2011 was consecutively included
in this retrospective analysis. Baseline and outcome data were
retrieved from computerized patient charts at the hospital, and
retrospective image analysis was done through the hospital’s
PACS system.
Patients
Patients were either admitted directly to the Karolinska
University Hospital or transferred from one of six referring
hospitals within the region. In addition, patients were occa-
sionally sent from more distant hospitals outside the primary
catchment area.
All patients arriving from referring hospitals had an
unenhanced computed tomography scan (CT) performed be-
fore transferring to the Karolinska University Hospital. In the
later part of the study, most patients also had a CTangiography
(CTA) before transfer. If a large infarction was revealed on the
CT scan, with a clear hypodensity exceeding 1/3 of the MCA
territory or with extensive brain stem involvement, the patient
was not treated with IVTand not transferred to the Karolinska.
If the patient was eligible for IVT, the infusion (0.9 mg/kg)
was initiated for all patients except for somewith basilar artery
occlusion, which was in accordancewith the stroke protocol at
the time. In the early years of the study, i.e., before 2010, the
result of the intravenous treatment was awaited, and the pa-
tient was re-evaluated after approximately 1 h, then transfer
was organized and the patient was sent to the Karolinska.
From 2010 and onwards, the patient was instead transferred
immediately after initiation of IVT, with ongoing treatment in
the ambulance. If a CTA had been performed, an additional
prerequisite for transfer was the presence of a large vessel
occlusion [principally internal carotid artery (ICA), middle
cerebral artery (MCA); segment M1 or M2 or basilar artery
(BA)]. Patients that were non-eligible for IVTwere transferred
if no large infarct was detected and endovascular treatment
could be initiated within 8 h after symptom onset. In addition,
only patients with a NIHSS score of 8–30 (from 2010 changed
to 6–25) without severe comorbidities were considered.
Exception was made for a few patients with NIHSS <6 if the
symptoms included aphasia. The reason for the upper limit of
NIHSS score was that, according to our experience, patients
with such high scores also had large manifest infarctions and
would gain little from endovascular treatment.
All patients arriving from outside hospitals were trans-
ferred directly to the Department of Neuroradiology, thus
bypassing the Emergency Room (ER), where representatives
for the Departments of Neurology, Anesthesiology, and
Neuroradiology met up. A quick neurological examination
was performed after which a non-enhanced CT was repeated
and complimented with a CT perfusion (CTP) and a CTA. If a
CTA had been executed already at the referring hospital, it was
repeated only if the patient had dramatically improved clinically.
Patients admitted directly to the Karolinska University
Hospital were examined clinically in the ER and brought to
the CT scanner with minimal time delay where the same
“stroke protocol” was performed (CT, CTA, and CTP). If
these patients were eligible for IVT, it was initiated immedi-
ately after the scanning.
All patients were subsequently brought directly to the
angio suite, some with ongoing infusion of alteplase, where
preparation for thrombectomy began. After having read the
scans, the decision whether to proceed with thrombectomy or
not was made jointly by the stroke neurologist and the
neurointerventionist on call. Mechanical thrombectomy was
considered for all patients with remaining symptoms, a large
vessel occlusion and with no large infarct as interpreted from
the CT, CTP, and CTA source images. In order to reduce the
risk of reperfusion hematomas, ongoing infusions of alteplase
were terminated when a guide catheter had been positioned,
and it was likely that the thrombectomy would be technically
feasible. The angiography suite preparations were aborted in
case of clinical improvement or if the presence of an already
large infarct could be determined based on the CT, the CT
source images, and the CTP.
The study was approved by the research ethics committee
at the Karolinska Institute, and no individual consent was
collected before inclusion in the study.
Thrombectomy technique
The Merci retrievers (Concentric Medical/Stryker
Neurovascular, Mountain View, California, USA), including
the X5, X6, L5, and L6 devices, as well as the V-series, were
used in the beginning of the study period. Since February
2009, different so-called stent retrievers were utilized:
Solitaire FR (ev3 Endovascular, Plymouth, MN, USA/
Covidien, Irvine, CA, USA), Trevo (Concentric Medical/
Stryker Neurovascular), IRIIS/Capture (Mindframe, Irvine,
CA, USA/Covidien), and Opticell (MindFrame/Covidien).
For most cases, the standard thrombectomy procedure
began with placing the tip of an 80-cm long introducer sheath,
mostly an Arrow 8F (Arrow International, PA, USA) in the
common carotid artery, just below the bifurcation, in which an
8F Merci balloon guide catheter (Concentric Medical/Stryker
Neurovascular) was inserted with its tip positioned in the
proximal ICA. In case of a BA occlusion, a 6F Envoy
(Cordis Corporation International, Johnson and Johnson
Medical NV/SA, Waterloo, Belgium) or a 7F Guider (Boston
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Scientific, Natick, Massachusetts, USA/Stryker Neurovascular)
was most of the time used as guide catheter.
After confirming the presence of the thromboembolus on
an angiogram, a microcatheter was advanced through the
thrombus with the aid of a microguidewire. After release of
the stent retriever, centered at the obstructive blood clot, it was
left in place for approximately 5 min (3–10) before the actual
thrombectomy was performed. The balloon was inflated with
simultaneous aspiration in the guide catheter to create flow
reversal in the ICA. For early cases in the series, where the
Merci device was used, the device was positioned distal to the
thromboembolus.
For patients with so-called tandem occlusions in the ante-
rior circulation, i.e., a proximal carotid severe stenosis or
occlusion due to acute dissection or atherosclerosis, in addi-
tion to the MCA occlusion, the procedure was modified to
include angioplasty or carotid stenting as well as to sometimes
contain the use of an intermediate catheter, mostly the so-
called “distal access catheter” (DAC; Concentric Medical/
Stryker Neurovascular).
For a few patients, the underlying cause for the large vessel
occlusion was an intracranial stenosis. Also, for these patients,
the standard procedure was altered to include angioplasty and
sometimes stenting. Placement of a stent, extra- or intracrani-
ally, was, however, avoided when possible due to the need for
anti-aggregation, which in the context of a potential acute
ischemic infarct may impose a risk for a severe reperfusion
hematoma. If a stent was inserted, the patient received half the
recommended bolus dose (0.125 mg/kg body weight) of
abciximab (Reo-Pro; Eli Lilly, Sweden), but no infusion,
followed by acetylsalicylic acid (Trombyl; Pfizer AB,
Sollentuna, Sweden; bolus of 300 mg and then 75 mg daily
for a minimum of 6 months) and clopidogrel (Plavix; Bristol-
Myers Squibb AB, Bromma, Sweden; bolus of 300 mg and
then 75 mg daily for a minimum of 3 months) after approxi-
mately 24 h when a routine follow-up CTscan did not reveal a
significant hematoma.
As a supplement to the thrombectomy, for treating small
distal emboli, alteplase was sometimes infused intra-arterially
together with careful microcatheter and microguidewire ma-
nipulations. The dose of alteplase was maximized to 10 mg in
case the patient had received IVT, whereas up to 20 mg could
potentially be administered if no IVT had been given. Other
adjunctive therapies included 2–5 mg of intra-arterial
nicardipine (Cardene; PDL BioPharma Inc., Fremont, CA,
USA) during the procedure if there was a tendency to focal
vasospasm, and in the beginning of the series, acetylsalicylic
acid (bolus of 300 mg and then 75 mg daily) and low molec-
ular weight heparin (dalteparin sodium, Fragmin; Pfizer AB,
2,500 IU twice daily) were used after the procedure in non-
stented patients to avoid re-occlusion. For patients later in the
series (from 2010), usually, no anti-aggregation or low mo-
lecular weight heparin was administered post-procedure since
re-occlusion in the absence of a stent was found not to be a
significant problem.
Baseline and outcome data
Baseline and outcome data were retrieved from computer-
ized records at the hospital. National Institute of Health
Stroke Scale (NIHSS) score [17] and the modified Rankin
Scale (mRS) score [18] were used as outcome parameters.
A stroke neurologist assessed the NIHSS score before and
after each intervention. In case NIHSS score pre- or post-
treatment was not specifically noted in the records, but the
criteria was described in the text, we assessed the score
based on the text. In four cases of anterior circulation
stroke, it was not possible to access enough information
from the charts to assess a pre-treatment score, and in 13
patients, it was impossible to establish a post-treatment
score. Information on the mRS score was for the majority
(59 %) of patients obtained at follow-up 3 months after the
procedure. For a minority, the scoring was postponed until
6 months post-treatment and for 9 % of the cases, it was
delayed even more until maximum of 12 months after the
thrombectomy procedure. The mRS scoring was done by an
independent stroke neurologist or by a stroke research
nurse certified for such evaluations, who also, in a few
cases with missing mRS score estimated the value from
the description in the charts. Favorable outcome was de-
fined as a mRS score of 0–2, corresponding to indepen-
dence in activities of daily living.
All the angiographies performed at the time of
thrombectomy were re-evaluated by two of the authors
(ÅKS and TA) to obtain definitive information on pre-
and post-procedure mTICI score (thrombolysis in cerebral
infarction) [19, 20]. The mTICI score was defined as fol-
lows: 0=no perfusion; 1=penetration, but no distal branch
filling; 2a=perfusion with incomplete (<50 %) distal
branch filling; 2b=perfusion with incomplete (≥50 %) dis-
tal branch filling; and 3=full perfusion with filling of all
distal branches. A post-procedure mTICI score of ≥2b was
considered to represent a successful revascularization. One
of the authors (ÅKS) also re-examined all pre- and post-
procedure unenhanced CT scans to obtain ASPECTS scores
(Alberta Stroke Program Early CT Score) [21] and to de-
termine the presence of any post-interventional hemor-
rhage. Hemorrhagic transformation was classified into
hemorrhagic infarction (HI) type 1 and 2 and parenchymal
hematoma (PH) type 1, type 2, and remote parenchymal
hematoma (PHr-2) in accordance with the ECASS defini-
tions [22]. We defined symptomatic intracranial hemor-
rhage according to the SITS-MOST definition: a PH-2
(blood clot exceeding 30 % of the infarcted volume with
significant space occupying effect) or subarachnoid hem-
orrhage on the post-treatment imaging scan leading to a
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decline in NIHSS of ≥4 points or causing death (mRS 6)
within 36 h [23].
For the statistical analysis, we used SAS statistical software
(V.9.1; SAS Institute Inc.). Ninety-five percent confidence inter-
vals (95%CI)were calculated assuming a binomial distribution.
For testing independence between outcome and exposure vari-
ables, we used Pearson’s exact chi-squared tests. Observations
with missing values were excluded. A p value <0.05 was
considered statistically significant.
Since a delayed assessment of mRS score may lead to an
overestimation of patients with good outcome, we assessed the
potential impact of the delayed mRS assessments by doing
sensitivity analyses where an extra point was added to the mRS
score for all patients whowere assessed after more than 6months.
Test for trends were done by analyzing categories as con-
tinuous variables in logistic regression using the PROC
LOGISTIC statement in SAS™.
Results
Baseline data
Baseline data about the patients are presented in Table 1.
During the study period, 240 patients were selected for
thrombectomy, and of these, 192 had an anterior circulation
occlusion. A more detailed presentation on the results on
patients with stroke in the posterior circulation has been
presented elsewhere [24], and we therefore focus on the
anterior circulation. Fifteen of the patients in the study were
previously included in the multicenter study by Davalos et al.
[25], all of them had anterior circulation strokes.
There were 138 (57.5 %) men and 102 (42.5 %) women;
45 % of the patients were under the age of 65, 46 % between
65 and 79, and 9 % were ≥80 years old. The median NIHSS
score was 16 (16 for the anterior circulation and 11 for the
posterior circulation). Ninety-six patients (40 %) were treated
with IVT before the endovascular intervention. Baseline mRS,
i.e., the functional status of the patients before the present
stroke, was one or more in 18 % of the cases. In two patients,
the procedure failed, as it was impossible to enter the intra-
cranial circulation; in one case due to severe tortuosity of the
carotids and in the other due to an ICA dissection, both
reported as having a missing mTICI score. In one patient, it
was impossible to report ASPECT before the intervention
because no CT was performed as the patient was transported
straight from the operating room to the angiography table
because of distal MCA (M2) thromboembolus after MCA
bifurcation aneurysm surgery. Two hundred nineteen (91 %)
of the occlusions were graded as mTICI 0 before the interven-
tion, i.e., a complete occlusion of that vessel. There was no
significant difference in baseline characteristics between pa-
tients treated and not treated with IVT.
Radiological and clinical outcome
The radiological and clinical results of the thrombectomies are
presented in Table 2. Seventy-two percent of the patients had
their final angiography runs graded as mTICI≥2b (successful
recanalization) and 7 % as mTICI 0 (no recanalization).
During the study period, NIHSSwas not generally assessed
for patients with posterior circulation strokes. We therefore
present data on NIHSS for anterior circulation strokes only.
The NIHSS score improved by 4 or more points in 63% of the
patients during the primary care, with NIHSS pre- or post-
intervention missing in 7.3 % of the cases.
Good functional outcome (mRS 0–2) was achieved in 50%
(120/240) of all patients. The figure for the subgroup of
patients with an anterior circulation stroke was almost identi-
cal (49 %, 95/192). Finally, 47 % (42/89) of patients that had
received IVT before the endovascular procedure had a good
functional outcome compared to 51 %(53/103) of those that
did not receive IVT. For patients with no neurological deficit
prior to stroke onset (i.e., mRS=0 before stroke), the propor-
tion with good functional outcome was 54 %.
Serious adverse events
Device-related problems were accounted in six patients, pos-
sible to solve in five of those cases, but in one patient, the
pusher wire broke, the device was left in place, and a carotid
stent had to be inserted to hold the wire in place and avoid
migration (Table 3). It did not cause any clinical symptoms,
but added an extra risk for the patient due to the need of anti-
aggregation treatment.
Procedure-related complications were encountered in 16
patients. Dissections were caused in seven of those, six of
which did not lead to any clinical deterioration. In one case,
there was a suspicion of excessive force during the
thrombectomy causing damage to the lenticostriate arteries,
leading to a mortal intracerebral hemorrhage. In eight patients,
a vessel perforation occurred during the procedure, one of
them located in the common iliac artery. Of the remaining
seven intracranial vessel perforations, two causedmortal hem-
orrhages. Two other cases were treated by parent vessel oc-
clusion with coils, not causing any increase in NIHSS score.
The remaining three intracranial perforations did not need any
further endovascular treatment nor did they cause any clinical
deterioration. In one patient, an air emboli was seen on the
angiogram, but it did not cause any clinical symptoms. In
total, out of 16 procedure-related complications, only three
cases resulted in clinical deterioration or death.
Small hemorrhages, not causing any mass effect, were
commonly seen, but such small bleeds never resulted in a
detectable clinical deterioration. Eight patients (4.2 %), all of
them having the obstruction in the anterior circulation, suf-
fered from a symptomatic intracerebral hemorrhage according
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to the SITS-MOST definition [8]. These hemorrhages were
located in the infarcted territory (so-called “reperfusion hema-
tomas”), most of which occurred a few hours after the proce-
dure. In addition, three hemorrhages were caused during the
procedure as described above, resulting in a total rate of
symptomatic intracranial hemorrhage of 5.7 % in the anterior
circulation (4.6% in total). For patients treatedwith IVT prior to
thrombectomy, there was more than twofold increase in risk for
symptomatic hemorrhage, but this increase in risk was not sta-
tistically significant (OR 2.1, 95 % CI 0.60–7.47). In this study,
no symptomatic hemorrhage was seen in patients ≥80 years old,
and there were no significant associations between the incidence
of symptomatic hematomas and sex, age, baseline mRS, pre-
interventional NIHSS and ASPECT scores, or time between
disease onset and treatment.
Difference between thrombectomy devices
We analyzed mTICI score post-thrombectomy, mRS at follow-
up, and serious adverse events by different endovascular recan-
alization methods (Table 4). Non-stent retrievers alone were
used in 47 patients. Most of them were variants of the Merci
Table 1 Patient characteristics by thrombus location and pre-intervention IVT
Anterior and posterior circulation Anterior circulation
All IV tPA No IV tPA
nr % nr % nr % nr %
All 240 100.0 192 100.0 89 100.0 103 100.0
Sex Male 138 57.5 104 54.2 50 56.2 54 52.4
Female 102 42.5 88 45.8 39 43.8 49 47.6
Age 16–49 38 15.8 29 15.1 15 16.9 14 13.6
50–64 70 29.2 56 29.2 22 24.7 34 33.0
65–79 110 45.8 89 46.4 46 51.7 43 41.7
80–xx 22 9.2 18 9.4 6 6.7 12 11.7
mRS baseline 0 202 84.2 161 83.9 79 88.8 82 79.6
1 26 10.8 21 10.9 7 7.9 14 13.6
2 9 3.8 7 3.6 3 3.4 4 3.9
3 2 0.8 2 1.0 0 0.0 2 1.9
4 1 0.4 1 0.5 0 0.0 1 1.0
Time to Karolinska Within 3 h 95 39.6 80 41.7 38 42.7 42 40.8
3–4.5 h 45 18.8 34 17.7 27 30.3 7 6.8
More than 4.5 h 33 13.8 25 13.0 14 15.7 11 10.7
In hospital 32 13.3 26 13.5 4 4.5 22 21.4
Wake up 28 11.7 22 11.5 4 4.5 18 17.5
Missing 7 2.9 5 2.6 2 2.2 3 2.9
iv rtPa 96 40.0 89 46.4 89 100.0 0 0.0
NIHSS pre-thrombectomy (median =16) 0–5 6 3.1 1 1.1 5 4.9
6–11 39 20.3 17 19.1 22 21.4
12–19 91 47.4 48 53.9 43 41.7
20–35 52 27.1 22 24.7 30 29.1
Missing 4 2.1 1 1.1 3 2.9
pre-ASPECT 0–5 29 15.1 18 20.2 11 10.7
6–7 57 29.7 29 32.6 28 27.2
8–9 72 37.5 35 39.3 37 35.9
10 32 16.7 7 7.9 25 24.3
Missing 2 1.0 0 0.0 2 1.9
Time to groin puncture Within 3 h 27 11.3 23 12.0 9 10.1 14 13.6
3–4.5 h 59 24.6 50 26.0 25 28.1 25 24.3
More than 4.5 h 87 36.3 66 34.4 45 50.6 21 20.4
In hospital 32 13.3 26 13.5 4 4.5 22 21.4
Wake up 28 11.7 22 11.5 4 4.5 18 17.5
Missing 7 2.9 5 2.6 2 2.2 3 2.9
mTICI pre-thrombectomy 0 219 91.3 180 93.8 83 93.3 97 94.2
1 10 4.2 6 3.1 4 4.5 2 1.9
2a 6 2.5 3 1.6 0 0.0 3 2.9
2b 2 0.8 1 0.5 1 1.1 0 0.0
Missing 3 1.3 2 1.0 1 1.1 1 1.0
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retriever, but in a few cases, the Amplatz snare was used. In 151
patients, stent retrievers were used, and in 15 cases, we used a
combination of these techniques. In 16 cases, no thrombectomy
device was used, but instead, intra-arterial thrombolysis was
performed alone or in combination with mechanical manipula-
tion with microcatheter and guidewire and/or aspiration. In five
Table 2 Number and proportion of post-thrombectomy recanalization (mTICI score), NIHSS score, NIHSS change, and modified Rankin Scale score
(mRS) by thrombus location and pre-intervention IVT
Anterior and posterior circulation Anterior circulation
All IV tPA No IV tPA
nr % nr % nr % nr %
All 240 100.0 192 100.0 89 100.0 103 100.0
mTICI post-thrombectomy 0 15 6.3 13 6.8 6 6.7 7 6.8
1 9 3.8 6 3.1 2 2.2 4 3.9
2a 42 17.5 33 17.2 17 19.1 16 15.5
2b 88 36.7 67 34.9 30 33.7 37 35.9
3 84 35.0 72 37.5 33 37.1 39 37.9
Missing 2 0.8 1 0.5 1 1.1 0 0.0
NIHSS post-thrombectomy (median=8) 0–5 81 42.2 33 37.1 48 46.6
6–11 35 18.2 17 19.1 18 17.5
12–19 42 21.9 23 25.8 19 18.4
20–35 21 10.9 10 11.2 11 10.7
Missing 13 6.8 6 6.7 7 6.8
NIHSS change (median=−6) ≥12 46 24.0 20 22.5 26 25.2
−11 to −4 75 39.1 32 36.0 43 41.7
−3 to +3 41 21.4 22 24.7 19 18.4
> +4 16 8.3 9 10.1 7 6.8
Missing 14 7.3 6 6.7 8 7.8
mRS at 3 months 0 16 6.7 12 6.3 5 5.6 7 6.8
1 49 20.4 43 22.4 20 22.5 23 22.3
2 55 22.9 40 20.8 17 19.1 23 22.3
3 48 20.0 40 20.8 21 23.6 19 18.4
4 27 11.3 25 13.0 12 13.5 13 12.6
5 8 3.3 4 2.1 2 2.2 2 1.9
6 35 14.6 26 13.5 12 13.5 14 13.6
Missing 2 0.8 2 1.0 0 0.0 2 1.9
Table 3 Adverse events by thrombus location and pre-intervention IVT
Anterior and posterior circulation Anterior circulation
All IV tPA No IV tPA
nr % nr % nr % nr %
All 240 100.0 192 100.0 89 100.0 103 100.0
Complications Device problems 6 2.5 5 2.6 3 3.4 2 1.9
Dissection 7 2.9 6 3.1 4 4.5 2 1.9
Perforation 8 3.3 8 4.2 2 2.2 6 5.8
Air emboli 1 0.4 1 0.5 0 0.0 1 1.0
Hemorrhage HI1 14 5.8 13 6.8 6 6.7 7 6.8
HI2 11 4.6 11 5.7 7 7.9 4 3.9
PH1 11 4.6 11 5.7 7 7.9 4 3.9
PH2 12 5.0 12 6.3 7 7.9 5 4.9
PHr1 0 0.0 0 0.0 0 0.0 0 0.0
PHr2 1 0.4 1 0.5 1 1.1 0 0.0
SAH/intraventr. 24 10.0 23 12.0 13 14.6 10 9.7
Vasospasm 19 7.9 15 7.8 9 10.1 6 5.8
Symptomatic hemorrhage 11 4.6 11 5.7 7 7.9 4 3.9
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patients, no endovascular treatment was performed at all since
it was not possible to reach the intracranial circulation (due to
severe tortuosity or dissection) or not possible to pass the
thrombus with the microcatheter. In one patient, the thrombus
had dissolved by the time of the first contrast injection during
angiography.
The proportion of patients with high mTICI scores post-
thrombectomy and low mRS scores at follow-up was higher
with stent retrievers thanwith non-stent retrievers (Figs. 1 and 2),
and also, the incidence of symptomatic hemorrhage (Fig. 3) and
dissections was lower when stent retrievers were used, but the
differences between stent, non-stent, and the combination of
both were not statistically significant. The incidence of device
problems and vasospasm was higher with the stent retrievers.
There were no statistically significant differences in outcome or
serious adverse events when extra- or intracranial stenting was
performed.
Discussion
In this study, we found that when performing mechanical
thrombectomy for ischemic stroke in the anterior circulation,
neither prior treatment with intravenous thrombolysis nor
high-attained age was significantly associated with risk for
symptomatic intracranial hemorrhage. The proportion of all
Table 4 Outcome (mTICI post-thrombectomy and mRS) and selected adverse events by endovascular recanalization method
Total Non-stent retrievera Stent retrieversb Combinationc IAT mmd No interventione
nr % nr % nr % nr % nr % nr %
All 237 100.0 47 100.0 151 100.0 15 100.0 16 100.0 6 100.0
mTICI post-thrombectomy 0 15 6.3 1 2.1 3 2.0 1 6.7 5 31.3 5 83.3
1 9 3.8 3 6.4 5 3.3 0 0.0 1 6.3 0 0.0
2a 41 17.3 13 27.7 23 15.2 3 20.0 2 12.5 0 0.0
2b 88 37.1 19 40.4 54 35.8 7 46.7 7 43.8 1 16.7
3 84 35.4 12 25.5 67 44.4 4 26.7 1 6.3 0 0.0
mRS at 3 months 0 16 6.8 1 2.1 11 7.3 2 13.3 2 12.5 0 0.0
1 49 20.7 6 12.8 38 25.2 2 13.3 2 12.5 1 16.7
2 54 22.8 12 25.5 34 22.5 1 6.7 5 31.3 2 33.3
3 48 20.3 14 29.8 25 16.6 3 20.0 4 25.0 2 33.3
4 27 11.4 2 4.3 18 11.9 4 26.7 2 12.5 1 16.7
5 8 3.4 1 2.1 5 3.3 1 6.7 0 0.0 1 16.7
6 35 14.8 11 23.4 20 13.2 2 13.3 1 6.3 1 16.7
Complications Device problems 6 2.5 0 0.0 6 4.0 0 0.0 0 0.0 0 0.0
Dissection 6 2.5 2 4.3 4 2.6 0 0.0 0 0.0 0 0.0
Perforation 8 3.4 2 4.3 5 3.3 1 6.7 0 0.0 0 0.0
Vasospasm 19 8.0 1 2.1 17 11.3 1 6.7 0 0.0 0 0.0
Symptomatic hemorrhage 11 4.6 4 8.5 7 4.6 0 0.0 0 0.0 0 0.0
a Non-stent retrievers: Merci (48), Amplatz (1). The figures do not add up because of more than one retriever being used in the same patient
b Stent retrievers: Solitaire (107), Trevo (23), IRIIS (20), Opticell (13), and Capture (9)
c Combination of stent and non-stent retrievers
d IAT alone or in combination with mechanical manipulation with microcatheter and guidewire and/or aspiration
e No intervention performed. In five cases, it was not possible to reach the intracranial circulation or pass the thrombus, and in one case, the thrombus had
dissolved
Fig 1 mTICI score post-
thrombectomy, total (237
patients), stent retrievers (151
patients), and non-stent retrievers
(mainly Merci) (47 patients)
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treated patients with favorable outcome after thrombectomy
was 50 %, and 54 % when restricting the analysis to patients
with no neurological deficits prior to stroke onset.
We found that by treating acute occlusions of the large
cerebral vessels with mechanical thrombectomy, we could
restore flow in 72 % of the patients (mTICI ≥2b), and 50 %
of all patients had gained independence (mRS 0–2) at follow-
up. In cases where we used only stent retrievers, mTICI ≥2b
was established in 80 % compared to 65 % when non-stent
retrievers were used (no statistical difference). In a recent
retrospective multicenter study of patients treated with the
Solitaire FR device [25], mTICI ≥2b was established in
85 %. Even so, there was no difference in the rate of indepen-
dent patients (54 vs 55 %) at follow-up between that and the
present study. In the SWIFT trial [26], Solitaire was compared
with the Merci Retrieval System. ATIMI score [27] of 2 or 3
was regarded as a successful recanalization achieved in 61 %
of the Solitaire FR-treated patients, but only in 24 % of the
patients treated with Merci. In spite of this relatively low
percentage of revascularization success, also for the Solitaire
FR, 58 % of the patients treated with that device reached a
mRS score of 0–2 at 3 months follow-up. In a third recent
study comparing the TREVO device with Merci [11], the
results were slightly different as compared to SWIFT. In this
TREVO 2-study, recanalization defined as mTICI ≥2b was
seen in 86 % of the stent retriever treated patients, but only
40 % of them reached independence (mRS 0–2) after 90 days.
A higher independence rate (55 %) was seen in the TREVO
EU study [28] with the same device although with a slightly
lower recanalization rate (78.3 %). Importantly, this study
included almost half of the patients within 3 h (onset to groin
puncture) while the corresponding delay in the first TREVO 2
study was 4.7 h. In our study, several different devices were
used (Solitaire, TREVO, Opticell, IRIIS, and Merci), more or
less from the starting point of their European approval.
Symptomatic hemorrhages occurred in 4.6 % of the cases
(5.7 % in the anterior circulation). This proportion is higher
than the 1.8% SICH reported for patients in the SITS-MOST
registry [23]. The patients in our study, however, had a median
NIHSS score of 16 compared to 12 in the SITS-MOST
database, and 36.3% of patients were treated more than 4.5 h
after onset of symptoms compared to less than 1 % in SITS-
MOST [23, 29]. Since it has been shown that both pre-
treatment NIHSS score and time to treatment are important
risk factors for SICH [30], it is likely that the high proportion
of SICH in our study at least in part is due to more severely ill
patients. None of the symptomatic hemorrhages occurred in
the oldest patient group (>80 years). Patients receiving intra-
venous therapy before the mechanical thrombectomy proce-
dure did not have a significantly higher rate of symptomatic
hemorrhages compared to patients that did not receive IVT. In
consequence, mechanical thrombectomy seems safe to per-
form even in old patients as well as in those receiving intra-
venous fibrinolytic therapy.
Strengths of the present single-center study include study
size and the consistency by which the acute stroke patients
were selected and treated. Other strengths were the possibility
to have access to updated medical records of all patients, and
that all consecutive patients were included in the study. Even
though protocol changes in the patient flow were made during
Fig 2 mRS scale score 3 months
post-thrombectomy, total
(237 patients), stent retrievers
(151 patients), and non-stent
retrievers (mainly Merci)
(47 patients)
Fig 3 Symptomatic intracranial
hemorrhage (SICH)
post-thrombectomy, total
(237 patients), stent retrievers
(151 patients), and non-stent
retrievers (mainly Merci)
(47 patients)
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the study period in order to decrease time delay and treat
patients faster, the principles of patient selection and basic
treatment techniques remained intact.
There are three limitations in the study. Firstly, since the
study was not based on patients selected according to
predefined criteria, but on all patients referred to the depart-
ment, the study is hampered by missing data. For example, for
some patients, there are missing data on post-interventional
NIHSS score (7 %). To address this problem, we treated all
patients with missing information on post-interventional
NIHSS score as non-successful thrombectomies. This ap-
proach reduces the risk of over-interpreting the benefits of
the procedure. For missing information on mRS score after
3 months, we used the information gathered not after 3 months
but after six or more months instead. This may increase the
proportion of patients with favorable outcome. Reassuringly
though, adding an extra point to the mRS score of all the
patients with mRS assessed after more than 6 months only
marginally altered the results. The second limitation is that this
study emanates from a single center, limiting the possibility to
generalize the results. Thirdly, the observational design of the
study is subject to all limitations inherent with this design.
In summary, our results supports that mechanical
thrombectomy is a safe and effective method to restore blood
flow in selected patients suffering from an acute ischemic
stroke. Further prospective, multicenter studies comparing
mechanical thrombectomy to IVT that may confirm our re-
sults are ongoing.
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